Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Passive income can help secure your retirement, but building a dependable income is not easy. You must be able to identify ...

Dividend investors are likely to find the stock's 6.7% yield attractive. That yield is the result of a 100% dividend payout ratio -- meaning the company devotes all its profit to the payments -- so ...

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...